Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671339 · ClinicalTrials.gov registry record · Phase 1
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07671339: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07671339 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07671339, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.
Interventions
- DRUG Tislelizumab
- DRUG mFOLFIRINOX
- DRUG ELI-002 7P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06-22 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07671339
The ClinicalTrials.gov registry entry for NCT07671339 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tislelizumab is the first listed.
NCT07671339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07671339 about?
NCT07671339 is a clinical study titled "A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer". The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find o...
What is the current status of trial NCT07671339?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06-22. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07671339?
The interventions under investigation include: Tislelizumab (DRUG), mFOLFIRINOX (DRUG), ELI-002 7P (DRUG).
Who is sponsoring clinical trial NCT07671339?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.